On June 28, 2021, the European Commission’s (EC) Scientific Committee on Consumer Safety (SCCS) published its final opinion on platinum (nano), colloidal platinum (nano), and acetyl tetrapeptide-17 colloidal platinum (nano). The EC asked SCCS whether it considers the nanomaterials A (platinum and colloidal platinum ) and B (acetyl tetrapeptide-17 (and) colloidal platinum) safe when used in leave-on cosmetic products according to the maximum concentrations and specifications reported, taking into account reasonably foreseeable exposure conditions. Having considered the information provided by the notifiers and obtained from other sources, SCCS states that it “is of the opinion that it is not possible to carry out a safety assessment of any of the notified platinum nanomaterials due to limited or missing essential information.” According to SCCS, “[t]he limited amount of data” provided by the notifiers does not correspond to the requirements and data standards as indicated in the SCCS Guidance (SCCS 1611/19), and the SCCS Memorandum (SCCS/1524/13). For SCCS to provide a safety assessment, the notifiers must provide the necessary information, a summary of which is provided in Annex I of the final opinion. The EC also asked whether SCCS has any further scientific concerns with regard to the use of materials A and B in nano form in cosmetic products. In the absence of sufficient data to allow a safety assessment, SCCS states that it considered different aspects of platinum nanomaterials that could raise a concern over consumer safety. SCCS “concluded that there is a basis for concern that the use of platinum, colloidal platinum, and acetyl tetrapeptide-17 colloidal platinum (nano) in cosmetic products can pose a risk to the consumer.” According to the final opinion, “SCCS will be ready to assess any evidence provided to support safe use of the materials in cosmetic products.”